Flow Cytometric Detection of the Double-Positive (CD4+CD8+)/PD-1bright T-Cell Subset Is Useful in Diagnosing Nodular Lymphocyte-Predominant Hodgkin Lymphoma

被引:4
|
作者
Chen, Zhongchuan Will [1 ,2 ]
Wizniak, Juanita [1 ,2 ]
Shang, Chuquan [1 ,2 ]
Lai, Raymond [1 ]
机构
[1] Univ Alberta, Dept Lab Med & Pathol, 10150 102 St NW 200, Edmonton, AB T5J 5E2, Canada
[2] Alberta Precis Labs, Edmonton, AB, Canada
关键词
PD-1; EXPRESSION; PATHOGENESIS; POPULATIONS; PATTERNS; ANTIGEN;
D O I
10.5858/arpa.2020-0726-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is characterized by neoplastic lymphocyte-predominant cells frequently rimmed by CD3(+)/CD57(+)/programmed death receptor-1 (PD-1)(+) T cells. Because of the rarity of lymphocyte-predominant cells in most cases, flow cytometric studies on NLPHL often fail to show evidence of malignancy. Objective.-To evaluate the diagnostic utility of PD-1 in detecting NLPHL by flow cytometry, in conjunction with the CD4:CD8 ratio and the percentage of T cells doubly positive for CD4 and CD8. Design.-Flow cytometric data obtained from cases of NLPHL (n = 10), classic Hodgkin lymphoma (n = 20), B-cell non-Hodgkin lymphoma (n = 22), T-cell non-Hodgkin lymphoma (n = 5), benign lymphoid lesions (n = 20), angioimmunoblastic T-cell lymphomas (n = 6) and T-cell/histiocyte-rich large B-cell lymphomas (n = 2) were analyzed and compared. Results.-Compared with the other groups, NLPHL showed significantly higher values in the following parameters: CD4:CD8 ratio, percentage of T cells doubly positive for CD4 and CD8, percentage of PD-1-positive T cells, and median fluorescence intensity of PD-1 expression in the doubly positive for CD4 and CD8 subset. Using a scoring system (0-4) based on arbitrary cutoffs for these 4 parameters, all 10 NLPHL cases scored 3 or higher, as compared with only 3 cases from the other groups, producing an overall sensitivity of 100% and a specificity of 96% (72 of 75). Two of the 3 outliers were non-Hodgkin lymphoma, and both showed definitive immunophenotypic abnormalities leading to the correct diagnosis. The remaining outlier was a case of T-cell/histiocyte-rich large B-cell lymphoma. Conclusions.-The inclusion of anti-PD-1 in flow cytometry is useful for detecting NLPHL in fresh tissue samples, most of which would have otherwise been labeled as nondiagnostic or reactive lymphoid processes.
引用
收藏
页码:718 / 726
页数:9
相关论文
共 43 条
  • [21] INCREASE IN T-CELLS EXPRESSING THE GAMMA/DELTA RECEPTOR AND CD4+CD8+ DOUBLE-POSITIVE T-CELLS IN PRIMARY IMMUNODEFICIENCY COMPLICATED BY HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I INFECTION
    FURUKAWA, S
    SASAI, K
    MATSUBARA, T
    YABUTA, K
    HIRAMATSU, K
    YAMAMOTO, T
    SHIRAI, T
    OKUMURA, K
    BLOOD, 1992, 80 (12) : 3253 - 3255
  • [22] CD20-Negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with Rituximab -: A molecular analysis using loser capture microdissection
    Pijuan, L
    Vicioso, L
    Bellosillo, B
    Ferrer, MD
    Baró, T
    Pedro, C
    Lloreta-Trull, J
    Munné, A
    Serrano, S
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (10) : 1399 - 1403
  • [23] T-Cell Large Granular Lymphocytic Leukemia with Extremely Rare Immunophenotype (CD4/CD8 Double-Positive) Followed by Multiple Myeloma Diagnosis
    Soliman, Dina
    Sallam, Sherin
    Akiki, Susanna
    Mudawi, Deena
    Ibrahim, Feryal
    CASE REPORTS IN HEMATOLOGY, 2020, 2020
  • [24] CD95 ligand mediates T-cell receptor-induced apoptosis of a CD4+ CD8+ double positive thymic lymphoma
    Schmitz, I.
    Meyer, C.
    Schulze-Osthoff, K.
    ONCOGENE, 2006, 25 (58) : 7587 - 7596
  • [25] CD95 ligand mediates T-cell receptor-induced apoptosis of a CD4+ CD8+ double positive thymic lymphoma
    I Schmitz
    C Meyer
    K Schulze-Osthoff
    Oncogene, 2006, 25 : 7587 - 7596
  • [26] Paraoxonase 1 knockout rats have impaired T cell development at the CD4/CD8 double-negative to double-positive transition stage
    Lin Bai
    Guiying Shi
    Yuanwu Ma
    Li Zhang
    Feifei Guan
    Xu Zhang
    Yanfeng Xu
    Houzao Chen
    Lianfeng Zhang
    Scientific Reports, 8
  • [27] Paraoxonase 1 knockout rats have impaired T cell development at the CD4/CD8 double-negative to double-positive transition stage
    Bai, Lin
    Shi, Guiying
    Ma, Yuanwu
    Zhang, Li
    Guan, Feifei
    Zhang, Xu
    Xu, Yanfeng
    Chen, Houzao
    Zhang, Lianfeng
    SCIENTIFIC REPORTS, 2018, 8
  • [28] Notch induces human T-cell receptor γδ+ thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8 double-positive pathway
    S Van Coppernolle
    S Vanhee
    G Verstichel
    S Snauwaert
    A van der Spek
    I Velghe
    M Sinnesael
    M H Heemskerk
    T Taghon
    G Leclercq
    J Plum
    A W Langerak
    T Kerre
    B Vandekerckhove
    Leukemia, 2012, 26 : 127 - 138
  • [29] Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
    Denlinger, Nathan
    Song, No-Joon
    Zhang, Xiaoli
    Jeon, Hyeongseon
    Peterson, Chelsea
    Wang, Yi
    Reynolds, Kelsi
    Bolz, Robert M.
    Miao, Jessica
    Song, Chunhua
    Wu, Dayong
    Chan, Wing Keung
    Bezerra, Evandro
    Epperla, Narendranath
    Voorhees, Timothy J.
    Brammer, Jonathan
    Kittai, Adam S.
    Bond, David A.
    Sawalha, Yazeed
    Sigmund, Audrey
    Reneau, John C.
    Rubinstein, Mark P.
    Hanel, Walter
    Christian, Beth
    Baiocchi, Robert A.
    Maddocks, Kami
    Alinari, Lapo
    Vasu, Sumithira
    de Lima, Marcos
    Chung, Dongjun
    Jaglowski, Samantha
    Li, Zihai
    Huang, Xiaopei
    Yang, Yiping
    BLOOD ADVANCES, 2024, 8 (12) : 3140 - 3153
  • [30] Notch induces human T-cell receptor γδ plus thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8 double-positive pathway
    Van Coppernolle, S.
    Vanhee, S.
    Verstichel, G.
    Snauwaert, S.
    van der Spek, A.
    Velghe, I.
    Sinnesael, M.
    Heemskerk, M. H.
    Taghon, T.
    Leclercq, G.
    Plum, J.
    Langerak, A. W.
    Kerre, T.
    Vandekerckhove, B.
    LEUKEMIA, 2012, 26 (01) : 127 - 138